SOURCE: Biophan Technologies, Inc.

June 13, 2006 16:45 ET

Reminder - to Feature Live Press Conference for BioPhan Technologies, Inc.

W. HENRIETTA, NY -- (MARKET WIRE) -- June 13, 2006 -- will conduct a live interview with Michael Weiner, CEO of BioPhan Technologies, Inc. (OTCBB: BIPH) (FRANKFURT: BTN), on at 9:30 a.m. Central Time on Wednesday, June 14th, 2006. Interested parties may go to and download the free player enabling them to listen in for management's review of operations and discussion of future prospects. This live broadcast is available to anyone at any computer connected to the internet. This should prove to be an eye-opening and enriching experience for all of those associated with BioPhan Technologies, Inc. (BIPH).

About is the only online destination that brings real microcap news to investors and features live interaction with companies from the Bulletin Board, Pink Sheets, and Amex. Featuring Live Press Conferences, All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and "The MicroBlog," gives microcap investors the information source necessary to trade in the markets. boasts being the largest true news company reporting on microcap traded stocks.

BioPhan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. BioPhan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD™, a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, BioPhan and its licensors now hold a total of over 200 U.S. and foreign patents, licenses, or applications. This total includes 56 issued U.S. patents, and over 100 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. BioPhan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. BioPhan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.

'Safe Harbor' Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. Although MN1 Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any assumption could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion should not be regarded as a representation by MN1 Inc. or any other person that the objective and plans of MN1 Inc. will be achieved.

Contact Information

  • Robert Ford
    Market News First
    Email Contact
    469-385-9855 ex. 801